These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15714755)

  • 1. Effect of ketanserin on platelet function and bleeding time in uremic patients treated with erythropoietin.
    Malyszko J; Pawlak K; Borawski J; Malyszko JS; Mysliwiec M
    Thromb Res; 1995 Jun; 78(6):541-6. PubMed ID: 15714755
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term effects of erythropoietin on platelet serotonin storage and platelet aggregation in hemodialysis patients with reference to ketanserin treatment.
    Borawski J; Rydzewski A; Pawlak K; Azzadin A; Buczko W; Mysliwiec M
    Thromb Res; 1998 May; 90(4):171-80. PubMed ID: 9692616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma.
    Zwaginga JJ; IJsseldijk MJ; de Groot PG; Kooistra M; Vos J; van Es A; Koomans HA; Struyvenberg A; Sixma JJ
    Thromb Haemost; 1991 Dec; 66(6):638-47. PubMed ID: 1665596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin and uremic platelet aggregation in vivo and in vitro.
    Malyszko JS; Malyszko J; Pawlak K; Mysliwiec M
    Int J Clin Lab Res; 1996; 26(3):199-202. PubMed ID: 8905452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of recombinant human erythropoietin on hemostatic status in chronic uremic patients.
    Tsao CJ; Kao RH; Cheng TY; Huang CC; Chang SL; Lee FN
    Int J Hematol; 1992 Apr; 55(2):197-203. PubMed ID: 1511168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Platelet aggregation during the recombinant human erythropoietin (rHuEPO) treatment of patients with uremia].
    Mazerska M; Pawlak K; Azzadin A; Małyszko J; Małyszko J; Myśliwiec M; Buczko W
    Pol Arch Med Wewn; 1992 Oct; 88(4):230-7. PubMed ID: 1488323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human erythropoietin shortens the uraemic bleeding time without causing intravascular haemostatic activation.
    Gordge MP; Leaker B; Patel A; Oviasu E; Cameron JS; Neild GH
    Thromb Res; 1990 Jan; 57(2):171-82. PubMed ID: 2315882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenosine 5'-diphosphate-induced platelet aggregation in uremia shows resistance to inhibition by the novel nitric oxide donor GEA 3175 but not by S-nitroso-N-acetylpenicillamine.
    Whiss PA; Larsson R
    Haemostasis; 1998; 28(5):260-7. PubMed ID: 10420076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inverse relationships between haemoglobin and ristocetin-induced platelet aggregation in haemodialysis patients under erythropoietin therapy.
    Borawski J; Rydzewski A; Mazerska M; Kalinowski M; Pawlak K; Mysliwiec M
    Nephrol Dial Transplant; 1996 Dec; 11(12):2444-8. PubMed ID: 9017620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ketanserin on bleeding time: a comparison with aspirin.
    Fraitag B; Bondard I; Duloroy J; Gorin NC
    Thromb Res; 1986 Oct; 44(2):261-4. PubMed ID: 3787570
    [No Abstract]   [Full Text] [Related]  

  • 11. Serotonin is involved in the pathogenesis of hypertension developing during erythropoietin treatment in uremic rats.
    Azzadin A; Mysliwiec J; Wollny T; Mysliwiec M; Buczko W
    Thromb Res; 1995 Feb; 77(3):217-24. PubMed ID: 7740514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin therapy in chronic uremia: the impact of normalization of hematocrit.
    Murphy ST; Parfrey PS
    Curr Opin Nephrol Hypertens; 1999 Sep; 8(5):573-8. PubMed ID: 10541220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of serotonergic mechanisms in the thrombotic complications in hemodialyzed patients treated with erythropoietin.
    Małyszko JS; Małyszko J; Pawlak K; Pawlak D; Buczko W; Myśliwiec M
    Nephron; 2000 Apr; 84(4):305-11. PubMed ID: 10754406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Extrinsic coagulation pathway in peritoneally dialyzed patients treated with erythropoietin].
    Małyszko J; Małyszko JS; Suchowierska E; Pawlak K; Myśliwiec M
    Przegl Lek; 2002; 59(3):139-41. PubMed ID: 12184025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human erythropoietin to correct uremic bleeding.
    Viganò G; Benigni A; Mendogni D; Mingardi G; Mecca G; Remuzzi G
    Am J Kidney Dis; 1991 Jul; 18(1):44-9. PubMed ID: 2063854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of platelet cytosolic calcium during erythropoietin therapy in uraemia.
    Fluck RJ; Roger SD; McMahon AC; Raine AE
    Nephrol Dial Transplant; 1994; 9(8):1109-14. PubMed ID: 7800209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and side effects of erythropoietin used in the treatment of anemia of uremic rats.
    Gretz N; Lasserre J; Kraft K; Waldherr R; Weidler B; Meisinger E; Strauch M
    Contrib Nephrol; 1988; 60():236-44. PubMed ID: 3345672
    [No Abstract]   [Full Text] [Related]  

  • 18. Hemodialysis, erythropoietin and megakaryocytopoiesis: factors in uremic thrombocytopathy and thrombophilia.
    Zwaginga JJ
    J Thromb Haemost; 2004 Aug; 2(8):1272-4. PubMed ID: 15304030
    [No Abstract]   [Full Text] [Related]  

  • 19. [Ketanserin decreases erythropoietin concentration in hemodialyzed patients on rHuEPO therapy].
    Borawski J; Mazerska M; Pawlak K; Myśliwiec M
    Pol Arch Med Wewn; 1994; 92 Spec No():14-20. PubMed ID: 7731894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effects of r-HuEPO on platelet function and coagulation factors in hemodialysis patients].
    Kinugasa E; Nabeshima K; Niikura K; Kawabe S; Akizawa T; Kitaoka T; Koshikawa S
    Nihon Jinzo Gakkai Shi; 1990 Oct; 32(10):1109-16. PubMed ID: 2287103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.